Assessment of Atrial Cardiomyopathy Using MRI as a Predictor of Cardiac Post-Operative Atrial Fibrillation After Cardiac Surgery.
Launched by CENTRE HOSPITALIER UNIVERSITAIRE DE SAINT ETIENNE · Dec 1, 2020
Trial Information
Current as of May 01, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at how well a special type of MRI can help predict a common heart problem called postoperative atrial fibrillation (POAF) after heart surgery, specifically coronary artery bypass grafting (CABG). POAF occurs when the heart's upper chambers don't beat in a regular rhythm after surgery, and it can lead to complications. The researchers believe that using advanced MRI techniques can provide more detailed information about heart changes, known as atrial cardiomyopathy, than current methods like echocardiograms (ultrasound of the heart) or electrocardiograms (tests that check the heart's rhythm).
To be eligible for the study, participants must be 18 years or older and scheduled for CABG surgery. They should also be part of a social security program and agree to join the study. However, those with certain health conditions, previous atrial fibrillation, or who are pregnant or breastfeeding cannot participate. If you join the study, you can expect to undergo an MRI that helps researchers understand the heart's condition better, which could lead to improved care and treatment for patients after heart surgery.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Age ≥ 18 years
- • Indication for surgical myocardial revascularization by coronary artery bypass
- • Patient affiliated or entitled to a social security scheme
- • Informed consent for participation in the study
- Exclusion Criteria:
- • Contraindication to cardiac MRI (Severe Kidney disease, Allergy to gadoliniumn, ...)
- • History of Atriale Fibrillation (AF)
- • Indication of cardiac valve surgery concomitantly with Coronary Artery Bypass Grafting (CABG).
- • pregnant or breast-feeding women
About Centre Hospitalier Universitaire De Saint Etienne
The Centre Hospitalier Universitaire (CHU) de Saint-Étienne is a leading academic medical center in France, dedicated to advancing healthcare through innovative clinical research and high-quality patient care. With a robust infrastructure that supports a wide range of medical specialties, CHU de Saint-Étienne fosters collaboration between healthcare professionals, researchers, and academic institutions. The center is committed to conducting rigorous clinical trials that adhere to ethical standards and regulatory requirements, aiming to improve treatment outcomes and enhance the overall health of the community. Through its dedication to scientific excellence and patient-centered care, CHU de Saint-Étienne plays a pivotal role in the advancement of medical knowledge and the development of new therapeutic interventions.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Saint étienne, , France
Patients applied
Trial Officials
Jean-Baptiste GUICHARD, MD
Principal Investigator
CHU SAINT-ETIENNE
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials